Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
about
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
P2860
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Combination Therapy With Exena ...... us Metformin: The Qatar Study.
@en
Combination Therapy With Exena ...... us Metformin: The Qatar Study.
@nl
type
label
Combination Therapy With Exena ...... us Metformin: The Qatar Study.
@en
Combination Therapy With Exena ...... us Metformin: The Qatar Study.
@nl
prefLabel
Combination Therapy With Exena ...... us Metformin: The Qatar Study.
@en
Combination Therapy With Exena ...... us Metformin: The Qatar Study.
@nl
P2093
P2860
P921
P356
P1433
P1476
Combination Therapy With Exena ...... us Metformin: The Qatar Study.
@en
P2093
Amin Jayyousi
Ayman Megahed
Curtis Triplitt
John Adams
Mahmoud Zirie
Muhammad Abdul-Ghani
Osama Migahid
P2860
P304
P356
10.2337/DC16-1738
P407
P577
2017-01-17T00:00:00Z